Login to Your Account

Pharma: Other News To Note

Monday, June 4, 2012
• Ranbaxy Laboratories Inc., of Princeton, N.J., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., is planning to launch Absorica (isotretinoin) in the fourth quarter, now that the FDA has approved the drug for the treatment of severe recalcitrant nodular acne. Absorica is partnered with Mississauga, Ontario-based Cipher Pharmaceuticals Inc., which will receive royalties on net sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription